Latest news with #Colistimethate
Business Standard
4 days ago
- Business
- Business Standard
Gland Pharma gains after Q1 PAT climbs 50% YoY to Rs 215 cr
Gland Pharma advanced 1.36% to Rs 1,991.15 after the company's consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25. Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025. Profit before tax (PBT) stood at Rs 312.74 crore in Q1 FY26, up 43.29% from Rs 218.25 crore recorded in Q1 FY25. EBITDA for the quarter came in at Rs 367.8 crore, marking a 38.58% growth YoY. The EBITDA margin improved to 24%, compared to 19% in the same period last year. On the geographical revenue front, Revenue from the US market stood at Rs 744.3 crore (down 2.42% YoY), revenue from Europe was at Rs 330.2 crore (up 28.68% YoY), Canada, Australia, and New Zealand stood at Rs 73.9 crore (up 65.32% YoY), Revenue from India was at Rs 59.4 crore (up 12.71% YoY) and the rest of the world was at Rs 297.8 crore (up 4.52% YoY) during the period under review. Total capex for the quarter rose 23.39% to Rs 78.6 crore in Q1 FY26, compared to Rs 63.7 crore in the same period last year. The companys total R&D expenses were Rs 46 crore in Q1 FY26, representing 4.4% of revenue. During Q1 FY26, the company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (in three new strengths), Liraglutide, and Acetaminophen Bags. Additionally, one ANDA (Abbreviated New Drug Application) was filed and nine were approved in Q1 FY26, contributing to a cumulative total of 372 ANDA filings in the U.S. (325 approved, 47 pending). Srinivas Sadu, Executive Chairman of Gland Pharma, said, We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth Shyamakant Giri, CEO, Gland Pharma, said, This quarters performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth. At the same time, our continued focus on R&D, adherence to global quality standards, and investment in capability building position us to scale further, tap new markets, and deliver long-term value. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?
Gland Pharma share price today: Shares of pharmaceutical company, Gland Pharma, jumped over 6 per cent on Wednesday, August 6, 2025, hitting an intraday high of ₹2,089.40. At 9:35 AM, Gland Pharma shares were trading at ₹2,004.1, up over 2 per cent on the National Stock Exchange. In comparison, Nifty50 was trading largely flat, albeit with a negative bias, quoting 24,631.90 level, down by 17 points or 0.07 per cent. The shares of the company were trading just 6 per cent lower when compared to 52-week high of ₹2,220. The total market capitalisation of the company stood at ₹32,974.35 crore. The buying interest on the counter came after the company released its earnings for the first quarter of the financial year 2025-2026 (Q1FY26). Gland Pharma Q1FY26 earnings The pharma company's profit after tax (PAT) for the quarter ended June 30, 2025, stood at ₹215 crore, up 50 per cent from ₹143 crore reported in the corresponding quarter of the previous fiscal year. Consolidated revenue from operations figures stood at ₹1,505 crore in Q1FY26, as against ₹1,401 crore reported in the year-ago period, marking a rise of 7 per cent. Earnings before interest, taxes, depreciation and amortisation (Ebitda) figure advanced 39 per cent to ₹367 crore during the quarter under review as compared to ₹265 crore reported in the first quarter of the last fiscal year. PAT margins stood at 14 per cent in Q1FY26. The figure stood at 10 per cent in the year-ago period. That apart, the company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen Bags. 'This quarter's performance, with improved margins and Cenexi achieving Ebitda break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth," said Shyamakant Giri, chief executive officer of Gland Pharma. What should investors do? The pharma company reported a strong double-digit rise in earnings after four quarters of consecutive decline. While the company's core market sales remained moderate, analysts at Motilal Oswal Financial Services believe that new launches will improve the outlook for the coming quarters. The brokerage firm has maintained a 'Buy' rating on the stock with a target price (TP) of ₹2,340. "After three years of earnings decline, we expect a compound annual growth rate (CAGR) of 14 per cent/20 per cent/27 per cent in revenue/Ebitda/Pat over FY25-27. Gland is fortifying its positioning in the complex injectable space through in-house product development as well as partnerships. It is in the process of adding capacity to cater to upcoming GLP-1 opportunities as well. Considering 1Q earnings growth and valuation, we maintain 'BUY' on the stock," the brokerage firm said. However, Ravi Singh, SVP-retail research at Religare Broking, has called for a cautious stance, saying that existing investors should wait for an extended price action. "On the weekly chart, the stock has strong resistance around ₹2,220 level, which can act as selling pressure and buyers may get trapped, so traders should cautiously watch the price action near this level. Overall, for now sentiments remain on the sideways to positive side with levels to be focused, existing investors can trail their positions to cost or book some profit near the immediate resistance of ₹2,120 and fresh positions can be recommended once it sustains above ₹2,120-₹2,150 level," said Ravi Singh.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
